Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Sprouse, G. Aghajanian (1987)
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonistsSynapse, 1
P. Chopin, M. Briley (1987)
Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmissionTrends in Pharmacological Sciences, 8
B. Richardson, G. Engel, P. Donatsch, P. Stadler (1985)
Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugsNature, 316
(1990)
Anxiolytic effects of the CCK antagonist devazepide and L - 365 , 260 in a conditioned suppression of drinking model
FOZARD FOZARD (1984)
MDL 72222: a potent and highly selective antagonist at neuronal 5‐hydroxytryptamine receptorsNaunyn-Schmiedebergs Arch. Pharmacol., 326
M. Raiteri, F. Angelini, G. Levi (1974)
A simple apparatus for studying the release of neurotransmitters from synaptosomes.European journal of pharmacology, 25 3
M. Raiteri, G. Bonanno, M. Marchi, G. Maura (1984)
Is there a functional linkage between neurotransmitter uptake mechanisms and presynaptic receptors?The Journal of pharmacology and experimental therapeutics, 231 3
P. Emson, C. Lee, J. Rehfeld (1980)
Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro.Life sciences, 26 25
A. Butler, J. Hill, S. Ireland, C. Jordan, M. Tyers (1988)
Pharmacological properties of GR38032F, a novel antagonist at 5‐HT3 receptorsBritish Journal of Pharmacology, 94
J. Vanderhaeghen, J. Signeau, W. Gepts (1975)
New peptide in the vertebrate CNS reacting with antigastrin antibodiesNature, 257
(1981)
The distribution of cholecystokinin in the central nervous system of the rat as determined by RIA
S. Ireland, M. Tyers (1987)
Pharmacological characterization of 5‐hydroxytryptamine‐induced depolarization of the rat isolated vagus nerveBritish Journal of Pharmacology, 90
A. Saito, H. Sankaran, I. Goldfine, J. Williams (1980)
Cholecystokinin receptors in the brain: characterization and distribution.Science, 208 4448
G. Dockray (1976)
Immunochemical evidence of cholecystokinin-like peptides in brainNature, 264
M. Beinfeld, D. Meyer, R. Eskay, R. Jensen, M. Brownstein (1981)
The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassayBrain Research, 212
M. Pinget, E. Straus, R. Yalow (1979)
Release of cholecystokinin peptides from a synaptosome-enriched fraction of rat cerebral cortex.Life sciences, 25 4
(1989)
5-HT3 receptors mediate inhibition
S. Peroutka, A. Hamik (1988)
[3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.European journal of pharmacology, 148 2
P. Emson, P. Marley (1983)
Cholecystokinin and Vasoactive Intestinal Polypeptide
J. Rehfeld (1978)
Immunochemical studies on cholecystokinin. I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin.The Journal of biological chemistry, 253 11
V. Derkach, A. Surprenant, R. North (1989)
5-HT3 receptors are membrane ion channelsNature, 339
J. Barnes, N. Barnes, B. Costall, R. Naylor, M. Tyers (1989)
5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissueNature, 338
(1976)
Immunochemical evidence of cholecystokininlike peptides
P. Bradley, G. Engel, W. Feniuk, J. Fozard, P. Humphrey, D. Middlemiss, E. Mylecharane, B. Richardson, P. Saxena (1986)
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 25
D. Deupree, S. Hsiao (1988)
Cholecystokinin octapeptide increases passive avoidance latencies in ratsPhysiology & Behavior, 42
Christian Waeber, Daniel Hoyer, JoséM. Palacios (1989)
5-Hydroxytryptamine3 receptors in the human brain: Autoradiographic visualization using [3H]ICS 205-930Neuroscience, 31
S. Iversen (1984)
5-HT and anxietyNeuropharmacology, 23
RICHARDSON RICHARDSON, ENGEL ENGEL (1986)
The pharmacology and function of 5‐HT 3 receptorsTrends Pharmacol. Sci., 9
B. Jones, B. Costall, A. Domeney, M. Kelly, R. Naylor, N. Oakley, M. Tyers (1988)
The potential anxiolytic activity of GR38032F, a 5‐HT3‐receptor antagonistBritish Journal of Pharmacology, 93
M. Bradford (1976)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Analytical biochemistry, 72
J. Fozard (1987)
5-HT: The Enigma VariationsTrends in Pharmacological Sciences, 8
R. Innis, S. Snyder (1980)
Distinct cholecystokinin receptors in brain and pancreas.Proceedings of the National Academy of Sciences of the United States of America, 77 11
(1989)
Cholecystokinin tetrapeptide induces
Brenda Costall, A. Domeney, R. Naylor, M. Tyers, M. Tyers (1987)
Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brainBritish Journal of Pharmacology, 92
C. Montigny (1989)
Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.Archives of General Psychiatry, 46
Gavin Kilpatrick, B. Jones, M. Tyers (1987)
Identification and distribution of 5-HT3 receptors in rat brain using radioligand bindingNature, 330
(1987)
Electrophysiological responses of serotonergic dorsal raphe neurones to 5 - HT 1 A and 5 - HTIB agonists
(1979)
Distribution of gastrin and cholecystokinin-like peptides in rat brain
J. Bradwejn, C. Montigny (1984)
Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neuronesNature, 312
DUMUIS (1989)
The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neuronsNaunyn-Schmiedebergs Arch. Pharmacol., 340
K. Goa, A. Ward (1986)
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.Drugs, 32 2
B. Richardson, G. Engel (1986)
The pharmacology and function of 5-HT3receptorsTrends in Neurosciences, 9
S. Ravard, C. Dourish (1990)
Cholecystokinin and anxiety.Trends in pharmacological sciences, 11 7
(1990)
5-HT3 receptors in anxiety disorders
John Hughes, P. Boden, Brenda Costall, A. Domeney, E. Kelly, D. Horwell, J. Hunter, R. Pinnock, G. Woodruff (1990)
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.Proceedings of the National Academy of Sciences of the United States of America, 87 17
M. Pinget, E. Straus, R. Yalow (1978)
Localization of cholecystokinin-like immunoreactivity in isolated nerve terminals.Proceedings of the National Academy of Sciences of the United States of America, 75 12
1 The effects of 5‐hydroxytryptamine (5‐HT) on the release of cholecystokinin‐like immunoreactivity (CCK‐LI) were examined in synaptosomes prepared from rat cerebral cortex and nucleus accumbens and depolarized by superfusion with 15 mm KCl. 2 In both areas 5‐HT, tested between 0.1 and 100 nm, increased the calcium‐dependent, depolarization‐evoked CCK‐LI release in a concentration‐related manner. The concentration‐response curves did not differ significantly between the two brain areas (EC50: 0.4 + 0.045 nm and 0.48 ± 0.053 nm, respectively, in cortical and n. accumbens synaptosomes; maximal effect: about 60% at 10 nm 5‐HT). 3 The 5‐HT1/5‐WT2 receptor antagonist methiothepin (300 nm) did not affect the CCK‐LI release elicited by 10 nm 5‐HT. However, the effects of 10 nm 5‐HT were antagonized in a concentration‐dependent manner by the 5‐HT3 receptor antagonists (3α‐tropanyl)‐1H‐indole‐3‐carboxylic acid ester (ICS 205–930; 0.1–100 nm; IC50: 3.56 ± 0.42 nm in the cortex and 3.90 ± 0.50 nm in the n. accumbens) and ondasetron (IC50: 8.15 + 0.73 nm in the cerebral cortex). 5‐HT (10 nm) was also strongly antagonized by 100 nm 1αH, 3α5αH‐tropan‐3‐yl‐3,5‐dichlorobenzoate (MDL 72222) another blocker of the 5‐HT3 receptor. Moreover, the 5‐HT3 receptor agonist 1‐phenylbiguanide (tested in the cerebral cortex between 0.1 and 100 nm) enhanced CCK‐LI release in a manner almost identical to that of 5‐HT (EC50 = 0.64 + 0.071 nm). 4 It is concluded that 5‐HT can act as a potent releaser of CCK‐LI in rat cerebrocortex and nucleus accumbens through the activation of receptors of the 5‐HT3 type situated on the CCK‐releasing terminals. This interaction may provide a rationale for the clinical development of both 5‐HT3 and CCK receptor antagonists as novel anxiolytic drugs.
British Journal of Pharmacology – Wiley
Published: Jul 1, 1991
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.